IGF-1 LR3

Evidence limitations: The safety profile for IGF-1 LR3 is based on very limited human data. Most available evidence comes from animal studies and in vitro research, with no completed clinical trials specifically evaluating safety in humans.

Known Side Effects

Based on the limited available evidence, potential adverse effects may include:

Metabolic effects:

• Altered glucose metabolism and insulin sensitivity (based on animal studies showing effects on glucose-stimulated insulin secretion)
• Potential hypoglycemia risk due to insulin-like effects

Other potential effects:

• The evidence is insufficient to establish a comprehensive side effect profile in humans

Contraindications

Absolute contraindications are not established due to lack of human clinical data. However, based on the mechanism of action, IGF-1 LR3 should likely be avoided in:

• Active malignancy or history of cancer (IGF-1 can promote cell proliferation)
• Diabetic retinopathy or other proliferative conditions
• Pregnancy and breastfeeding (safety not established)

Drug Interactions

No specific drug interactions have been established in the available literature. However, theoretical interactions may occur with:

• Insulin and other diabetes medications (potential additive hypoglycemic effects)
• Growth hormone and related compounds

High-Risk Populations

The following populations should avoid IGF-1 LR3 or use with extreme caution:

• Children and adolescents (effects on normal growth and development unknown)
• Pregnant and breastfeeding women (no safety data available)
• Individuals with diabetes (potential effects on glucose metabolism)
• Cancer patients or those with cancer history (theoretical tumor promotion risk)
• Elderly patients (increased sensitivity to metabolic effects possible)

Critical Safety Gaps

The evidence base for human safety is extremely thin. Key limitations include:

• No completed human clinical trials focused on safety
• Limited long-term safety data even in animal models
• Unknown optimal dosing ranges for humans
• Unclear drug interaction profile
• No established monitoring parameters

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a qualified healthcare provider before considering any experimental therapies.